| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/12/2012 | CA2804143A1 Spiro-cyclic amine derivatives as s1p modulators |
| 01/12/2012 | CA2804137A1 Fused heterocyclic derivatives as s1p modulators |
| 01/12/2012 | CA2804124A1 Cannabis drug delivery and monitoring system |
| 01/12/2012 | CA2804113A1 Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament |
| 01/12/2012 | CA2804112A1 (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
| 01/12/2012 | CA2804107A1 Solifenacin salts |
| 01/12/2012 | CA2803900A1 Combinations of kinase inhibitors for the treatment of cancer |
| 01/12/2012 | CA2803880A1 Compounds for the inhibition of cellular proliferation |
| 01/12/2012 | CA2803717A1 (3-methylpyrrolidin-3-yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists |
| 01/12/2012 | CA2803670A1 Novel antibacterial compounds, methods of making them, and uses thereof |
| 01/12/2012 | CA2803580A1 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound |
| 01/12/2012 | CA2803545A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | CA2803539A1 Prokineticin 1 receptor antagonists for the treatment of pain |
| 01/12/2012 | CA2803448A1 Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| 01/12/2012 | CA2803248A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 01/12/2012 | CA2803228A1 Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster |
| 01/12/2012 | CA2803118A1 Sulfonamide derivatives as nav 1.7 inhibitors |
| 01/12/2012 | CA2803113A1 Treatment of blood cancer |
| 01/12/2012 | CA2803090A1 Crystalline form of a 3-phenoxymethylpyrrolidine compound |
| 01/12/2012 | CA2803004A1 Oral formulation of kinase inhibitors |
| 01/12/2012 | CA2802929A1 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| 01/12/2012 | CA2802832A1 Therapeutic agents 976 |
| 01/12/2012 | CA2802216A1 Tetrahydrocarboline derivative |
| 01/12/2012 | CA2802133A1 Use of 5.alpha.-androstane(alkyl)-3.beta.,5,6.beta.-triol in preparation of neuroprotective drugs |
| 01/12/2012 | CA2802132A1 Tetrahydro-pyrido-pyrimidine derivatives |
| 01/12/2012 | CA2801670A1 Heterocyclic antiviral compounds |
| 01/12/2012 | CA2801620A1 Novel gastro-retentive dosage forms comprising a gaba analog and an opioid |
| 01/12/2012 | CA2801583A1 Anellated pyridine compounds |
| 01/12/2012 | CA2801361A1 Resveratrol-containing compositions and methods of use for cardiac related diseases |
| 01/12/2012 | CA2800930A1 Novel spiroheterocyclic compounds as mglu5 antagonists |
| 01/11/2012 | EP2405023A2 Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
| 01/11/2012 | EP2405015A2 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 01/11/2012 | EP2405002A1 Compositions and methods for oligonucleotide formulations |
| 01/11/2012 | EP2405001A1 Nucleic acid complex and nucleic acid-delivering composition |
| 01/11/2012 | EP2404997A1 Method for enhancing function of t cell |
| 01/11/2012 | EP2404939A2 Low molecular weight heparin composition and uses thereof |
| 01/11/2012 | EP2404927A2 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 01/11/2012 | EP2404923A1 7-azabicyclo[2.2.1]heptane derivatives useful for promoting smoking cessation |
| 01/11/2012 | EP2404922A1 Quinoxaline compounds |
| 01/11/2012 | EP2404921A1 Salts of tetrahydroimidazo ý1,5-a¨pyrazine derivatives, preparation methods and pharmaceutical use thereof |
| 01/11/2012 | EP2404920A1 Crystalline form of Rivaroxaban dihydrate |
| 01/11/2012 | EP2404919A1 Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters. |
| 01/11/2012 | EP2404918A1 Pyridine derivative |
| 01/11/2012 | EP2404910A2 Polymorphs of 2-(3-cyano-4-Isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
| 01/11/2012 | EP2404909A1 Amide thiazole derivative, preparation method and uses thereof |
| 01/11/2012 | EP2404908A1 Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst |
| 01/11/2012 | EP2404907A1 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| 01/11/2012 | EP2404906A1 Methods of synthesizing pharmaceutical salts of a factor XA inhibitor |
| 01/11/2012 | EP2404905A1 New compounds |
| 01/11/2012 | EP2404904A1 5-lipoxygenase-activating protein (FLAP) inhibitors |
| 01/11/2012 | EP2404902A1 Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
| 01/11/2012 | EP2404901A1 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| 01/11/2012 | EP2404896A1 Cyclohexane derivative having npy y5 receptor antagonism |
| 01/11/2012 | EP2404895A1 Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
| 01/11/2012 | EP2404890A1 Hydroxyl compounds and compositions for cholesterol management and related uses |
| 01/11/2012 | EP2404619A1 Injectable composition composed of an injectable medication and a gel |
| 01/11/2012 | EP2404608A1 Combination use of cholestanol derivative |
| 01/11/2012 | EP2404607A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| 01/11/2012 | EP2404606A1 Ophthalmic compositions comprising a prostaglandin and a viscosity agent |
| 01/11/2012 | EP2404605A1 Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| 01/11/2012 | EP2404604A1 Salts of potassium ATP channel openers and uses thereof |
| 01/11/2012 | EP2404603A1 Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases |
| 01/11/2012 | EP2404602A1 Hedgehog pathway antagonists to treat cancer |
| 01/11/2012 | EP2404601A1 New drug combinations for the treatment of Malaria |
| 01/11/2012 | EP2404600A1 Use of the combination of a sinus current If inhibitor and an inhibitor of the angiotensin conversion enzyme for treating cardiac insufficiency |
| 01/11/2012 | EP2404599A1 Neuroprotective compounds |
| 01/11/2012 | EP2404598A1 Amino acid-conjugated cyanoacrylate polymer particles |
| 01/11/2012 | EP2404597A1 NOS-inhibitor L-NIL for use in chronic lung diseases |
| 01/11/2012 | EP2404596A1 Kit for Cancer Treatment and Pharmaceutical Composition for Cancer Treatment |
| 01/11/2012 | EP2404595A2 Method for manufacturing indanone derivatives |
| 01/11/2012 | EP2404594A1 Compositions comprising docetaxel with increased stability and methods for preparation thereof |
| 01/11/2012 | EP2404588A1 Package of solid pharmaceutical preparation |
| 01/11/2012 | EP2404502A2 Compositions containing pyrrolidone carboxylic acid (PCA) and metallic salts |
| 01/11/2012 | EP2403945A2 Rna molecules and therapeutic uses thereof |
| 01/11/2012 | EP2403860A2 Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
| 01/11/2012 | EP2403859A2 Molecular tweezers for the treatment of amyloid-related diseases |
| 01/11/2012 | EP2403857A1 Thienopyrimidine as cdc7 kinase inhibitors |
| 01/11/2012 | EP2403856A1 Methylenedioxybenzo [i]phenanthridine derivatives used to treat cancer |
| 01/11/2012 | EP2403855A1 Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof |
| 01/11/2012 | EP2403854A1 Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| 01/11/2012 | EP2403853A1 Pyrrolopyrimidines used as kinase inhibitors |
| 01/11/2012 | EP2403850A1 Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation |
| 01/11/2012 | EP2403849A1 Oxazole pyridine derivatives useful as s1p1 receptor agonists |
| 01/11/2012 | EP2403848A1 Pharmaceutical hypocholesterolemic compositions |
| 01/11/2012 | EP2403847A1 Triazine derivatives as kinase inhibitors |
| 01/11/2012 | EP2403846A1 Inhibitors of bruton's tyrosine kinase |
| 01/11/2012 | EP2403845A2 Improved process |
| 01/11/2012 | EP2403844A1 Heterocyclic antiviral compounds |
| 01/11/2012 | EP2403840A1 Derivatives of benzothiazines, preparation thereof and application thereof as drugs |
| 01/11/2012 | EP2403839A2 Neurotrophin mimetics and uses thereof |
| 01/11/2012 | EP2403835A1 Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators |
| 01/11/2012 | EP2403834A1 Fungicidal pyrazoles |
| 01/11/2012 | EP2403833A1 8-substituted quinolines and related analogs as sirtuin modulators |
| 01/11/2012 | EP2403832A1 N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| 01/11/2012 | EP2403830A2 Indole derivatives for treating neurodegenerative diseases |
| 01/11/2012 | EP2403551A2 Silk fibroin systems for antibiotic delivery |
| 01/11/2012 | EP2403533A1 Methods of enhancing peroxide activity |
| 01/11/2012 | EP2403517A1 Novel antiviral agent |
| 01/11/2012 | EP2403505A2 Therapeutic uses of mastic gum fractions |
| 01/11/2012 | EP2403504A1 Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties |